All the Drug Class Drugs
GIP and GLP-1 receptor agonist. Tirzepatide 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg. Multi-dose pre-filled pen. Sol. for SC inj. 4 X 2.5/5.0/7.5/10.0/12.5/15.0 mg
Starting dose is 2.5 mg once weekly. After 4 weeks, dose should be incr. to 5 mg once weekly. If needed, dose incr. can be made in 2.5 mg incr. after a min. of 4 weeks on the current dose. Recomm. maint. doses are 5 mg, 10 mg and 15 mg. Max. dose is 15 mg once weekly.
When added to existing metformin and/or sodium-glucose co-transporter 2 inhib. (SGLT2i) ther., current dose of metformin and/or SGLT2i can be continued. When added to existing ther. of a sulphonylurea and/or insulin, a reduct. in the dose of sulphonylurea or insulin may be considered to reduce risk of hypoglycaemia. Blood glucose self-monitoring is necessary to adjust the dose of sulphonylurea and insulin. A stepwise approach to insulin reduct. is recomm.
Tmt. of adults with insuffic. controlled type 2 diabetes mellitus as an adjunct to diet and exercise • as monother. when metformin is considered inappropriate due to intol. or contraindic. • in addition to other drugs for the tmt. of diabetes.
As an adjunct to a reduced-calorie diet and incr. phys. activity for weight management, including weight loss and weight maint., in adults with an initial Body Mass Index (BMI) of • ≥ 30 kg/m2 (obesity) or • ≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, CV dis., prediabetes, or type 2 diabetes mellitus). For trial results with respect to obstructive sleep apnoea (OSA) in adults with obesity, see full prescript. info.
C/I: Hypersens.
